[Acquired hemophilia A following BNT162b2 mRNA COVID-19 vaccination].
Rinsho Ketsueki
; 64(1): 35-41, 2023.
Article
in Japanese
| MEDLINE | ID: covidwho-2280501
ABSTRACT
Acquired hemophilia A (AHA) is a rare disease characteized by bleeding symptoms caused by decreased factor VIII activity due to the appearance of inhibitors to factor VIII triggered by malignancy or collagen disease. An 86-year-old woman developed purpura on her extremities after the first dose of the BNT162b2 mRNA COVID-19 vaccine. This symptom subsided after a few days. After the second dose of the BNT162b2 mRNA COVID-19 vaccine, purpura appeared again, and the patient was referred to our hospital Her APTT was remarkably prolonged to 110 seconds, and a cross-mixing test revealed an inhibitor pattern. Since FVIII activity was <1% and FVIII inhibitor was 51.6 BU, she was diagnosed with AHA. Prednisolone therapy was started, and coagulative complete remission was achieved. Because acquired hemophilia can develop after mRNA COVID-19 vaccination, as in this case, it is critical to monitor the appearance of bleeding symptom.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
BNT162 Vaccine
/
Hemophilia A
Type of study:
Case report
/
Observational study
/
Randomized controlled trials
Topics:
Long Covid
/
Vaccines
Limits:
Female
/
Humans
Language:
Japanese
Journal:
Rinsho Ketsueki
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS